Fig. 5: Olaparib and Sorafenib show a synergic effect in vitro and in vivo. | npj Breast Cancer

Fig. 5: Olaparib and Sorafenib show a synergic effect in vitro and in vivo.

From: TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC

Fig. 5

A The dose-response matrixes by SynergyFinder are based on CCK-8 results of HCC1806 and MDA-MB-231. Data are shown as the mean value of at least three independent experiments. B The synergy score by the ZIP model provided by SynergyFinder is based on the matrixes. C–F MDA-MB-231-Luc (1 × 107 cells/mouse) were injected into the right fourth breast pad. The mice were randomly divided into four groups with different setups. C, D Tumor volume. E Body weight. F In vivo bioluminescence. Data are shown as the mean ± SD. The significant level was identified by *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Two-way ANOVA analysis is used for tumor growth curves (D).

Back to article page